United Therapeutics Corporation

NasdaqGS:UTHR 주식 보고서

시가총액: US$16.8b

United Therapeutics 과거 수익 실적

과거 기준 확인 3/6

United Therapeutics은 연평균 30.7%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 수입이 증가했으며, 연간 19.3%였습니다. 매출은 연평균 13.7%의 비율로 증가했습니다. United Therapeutics의 자기자본이익률은 18.2%이고 순이익률은 40.3%입니다.

주요 정보

30.7%

수익 성장률

29.6%

EPS 성장률

Biotechs 산업 성장17.0%
매출 성장률13.7%
자기자본 수익률18.2%
순이익40.3%
최근 수익 업데이트30 Sep 2024

최근 과거 실적 업데이트

Recent updates

United Therapeutics: One To Believe In Despite Competitive Threats

Nov 14

Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

Oct 18
Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price

Sep 27
Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price

United Therapeutics: Economics Support Compounding Ability

Aug 20

With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

Jul 26
With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

Jul 04
United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market

Jun 13
United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market

United Therapeutics: Exciting Company With A Big Problem

Jun 02

We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease

Apr 05
We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease

United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects

Mar 20

Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?

Mar 15
Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?

Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings

Jan 02
Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings

United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

Dec 08
United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

Nov 16
Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

Sep 04
United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

Aug 07
Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

May 22
United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?

Apr 25
Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?

We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease

Feb 06
We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease

With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

Jan 16
With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

Oct 20
Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

United Therapeutics: Ability To Expand Tyvaso To Large IPF Market

Aug 24

Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?

Aug 04
Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?

수익 및 비용 분석

United Therapeutics 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

NasdaqGS:UTHR 수익, 비용 및 수입 (USD Millions )
날짜수익수익G+A 비용R&D 비용
30 Sep 242,7561,111607499
30 Jun 242,6171,069581480
31 Mar 242,4981,051533429
31 Dec 232,328985476408
30 Sep 232,204900499351
30 Jun 232,111872470332
31 Mar 231,981728481337
31 Dec 221,936727473323
30 Sep 221,860707448312
30 Jun 221,789631458324
31 Mar 221,768687429304
31 Dec 211,686476466410
30 Sep 211,655462499450
30 Jun 211,591471451440
31 Mar 211,506405444456
31 Dec 201,483515421358
30 Sep 201,410469364345
30 Jun 201,431430402362
31 Mar 201,443528336350
31 Dec 191,449-1043351,174
30 Sep 191,519-923131,199
30 Jun 191,530-1183241,214
31 Mar 191,601-1503671,220
31 Dec 181,628589269358
30 Sep 181,711543348333
30 Jun 181,744713285287
31 Mar 181,744484270264
31 Dec 171,725418333265
30 Sep 171,670509311218
30 Jun 171,632395363209
31 Mar 171,600657368184
31 Dec 161,599714319148
30 Sep 161,595708326157
30 Jun 161,5731,011209120
31 Mar 161,507904246135
31 Dec 151,466652453245
30 Sep 151,407663385241
30 Jun 151,351173604350
31 Mar 151,327186562340
31 Dec 141,289340381243
30 Sep 141,231194458293
30 Jun 141,203282350246
31 Mar 141,161250353261
31 Dec 131,117175394299

양질의 수익: UTHR 은 높은 수익을 보유하고 있습니다.

이익 마진 증가: UTHR 의 현재 순이익 이익률 (40.3%) 작년보다 낮습니다 (40.8%).


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: UTHR 지난 5년 동안 수익을 창출하여 매년 30.7% 수익을 올렸습니다.

성장 가속화: 지난 1년간 UTHR 의 수익 증가율( 23.5% )은 5년 평균( 30.7% 보다 낮습니다. 년도).

수익 대 산업: 지난 1년간 UTHR 수익 증가율( 23.5% )은 Biotechs 업계 16.6% 초과했습니다.


자기자본 수익률

높은 ROE: UTHR 의 자본 수익률( 18.2% )은 낮음으로 간주됩니다.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기